JW Pharma Acquires C&C Research Laboratories a Joint Venture with Chugai
Shots:
- JWP to acquire all stock of Chugai in C&C by 31 Dec 2019. C&C will be a wholly-owned subsidiary of JWP and will continue its R&D with independent management. Additionally- JWP and Chugai will cooperate on novel therapies developed by C&C
- The collaboration follows the succeeding of C&C in developing candidates for the treatment of atopic dermatitis and gout treatment
- C&C is a Korea based company developed JW1601 and URC102 to treat atopic dermatitis and gout respectively. JW1601 (PO) is an H4R antagonist expected to have anti-pruritic and anti-inflammatory with its IND submission to the US for PK study and is out-licensed to Leo Pharma in Aug 2018
Click here to read full press release/ article | Ref: Chugai Pharmaceutical | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
